| Description |
Sifalimumab (MEDI-545) is an anti-IFNα monoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. Sifalimumab can be used in systemic lupus erythematosus (SLE) research[1][2].
|
| Related Catalog |
|
| In Vitro |
Sifalimumab (3-36 μg/well; 72 h) attenuates lymphocyte cytotoxicity co-cultured with U-87MG[2]. Cell Viability Assay[2] Cell Line: U-87MG cells and AGS lymphocytes Concentration: 3-36 μg/well Incubation Time: 72 hours Result: Attenuated lymphocyte cytotoxicity triggered by IFN I (P<0.05).
|
| In Vivo |
Sifalimumab (subcutaneous injection; 30 mg/kg and 3 μg/g) treatment shows therapeutic effect and attenuates the lymphocyte infiltration[2]. Animal Model: Wild-type male BALB/c mice[2] Dosage: 30 mg/kg and 3 μg/g Administration: Subcutaneous injection; 30 mg/kg and 3 μg/g Result: Prevented the increase CpG-induced, decreasing CD86 fluorescence intensity by 1.9-fold (P < 0.05). Showed a potentially therapeutic effect attenuating the CpG-induced lymphocyte infiltration. Attenuated the CD45 increase (P<0.05).
|
| References |
[1]. Merrill JT, et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis. 2011 Nov;70(11):1905-13.
|
